Respiratory (25 companies · 9 conditions)

Conditions

Idiopathic Pulmonary Fibrosis 8 Rare Asthma 7 COPD 4 Acute Respiratory Distress Syndrome 3 Alpha-1 Antitrypsin Deficiency 3 Rare Cystic Fibrosis 3 Rare Obstructive Sleep Apnea 2 Progressive Pulmonary Fibrosis 2 Rare Bronchiectasis 1

Companies

Ticker	Company	Therapeutic areas	In Respiratory	Lead stage	Mkt cap	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	2	Phase 3	$677M	5
ACRS	Aclaris Therapeutics	DermatologyGI/Hepatology+1 Rare	1	Phase 2	$619M	8
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	1	Phase 2	$376M	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	1	Approved	$111M	10
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	4	Phase 2	—	9
BEAM	Beam Therapeutics	HematologyMetabolic+1 Rare	1	Phase 2	$2.73B	6
CLDX	Celldex Therapeutics	DermatologyImmunology+1	1	Phase 3	$2.35B	9
CNTB	Connect Biopharma	Respiratory	4	Phase 2	$45.9M	4
CTNM	Contineum Therapeutics	NeurologyRespiratory Rare	1	Phase 2	$374M	4
CRVS	Corvus Pharmaceuticals	DermatologyOncology+1 Rare	1	Phase 3	$889M	7
IXHL	Incannex Healthcare	NeurologyRespiratory	1	Phase 2	$28.1M	2
INSM	Insmed	CardiovascularImmunology+3 Rare	7	Approved	$25.1B	15
KYMR	Kymera Therapeutics	DermatologyImmunology+1 Rare	1	Phase 2	$11.2B	5
LQDA	Liquidia	CardiovascularImmunology+1 Rare	3	Approved	$3.97B	9
MLYS	Mineralys Therapeutics	CardiovascularRenal+1	1	NDA Submitted	$1.36B	3
INKT	MiNK Therapeutics	ImmunologyOncology+1 Rare	1	Phase 2	$52.8M	8
OMER	Omeros	HematologyNeurology+2 Rare	1	Approved	$1.22B	6
RNTX	Rein Therapeutics	Respiratory Rare	1	Phase 2	$53.0M	1
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	1	Phase 3	$4.8M	10
SRPT	Sarepta Therapeutics	NeurologyRespiratory Rare	1	Approved	$1.91B	11
SION	Sionna Therapeutics	Respiratory Rare	5	Phase 2	$148M	5
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	1	Phase 3	$4.35B	5
VTVT	vTv Therapeutics	HematologyMetabolic+1 Rare	1	Phase 3	$84.4M	9
WVE	Wave Life Sciences	MetabolicNeurology+1 Rare	1	Phase 2	$665M	5
ZYME	Zymeworks	OncologyRespiratory	1	Approved	$2.10B	11